WO1998046206A1 - Composition de creme pour l'epiderme - Google Patents

Composition de creme pour l'epiderme Download PDF

Info

Publication number
WO1998046206A1
WO1998046206A1 PCT/US1998/007430 US9807430W WO9846206A1 WO 1998046206 A1 WO1998046206 A1 WO 1998046206A1 US 9807430 W US9807430 W US 9807430W WO 9846206 A1 WO9846206 A1 WO 9846206A1
Authority
WO
WIPO (PCT)
Prior art keywords
composition
amount
skin
vitamin
alanine
Prior art date
Application number
PCT/US1998/007430
Other languages
English (en)
Inventor
Yveta Germano
Original Assignee
Peregrine Pharmaceutical, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Peregrine Pharmaceutical, Inc. filed Critical Peregrine Pharmaceutical, Inc.
Priority to AU69694/98A priority Critical patent/AU6969498A/en
Publication of WO1998046206A1 publication Critical patent/WO1998046206A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
    • A61K8/44—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/60—Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/67—Vitamins
    • A61K8/673—Vitamin B group
    • A61K8/675—Vitamin B3 or vitamin B3 active, e.g. nicotinamide, nicotinic acid, nicotinyl aldehyde
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/67—Vitamins
    • A61K8/676—Ascorbic acid, i.e. vitamin C

Definitions

  • the present invention is directed to the field of skin cream compositions.
  • Skin is a complex, sensitive organ that serves many functions necessary for well-being and maintenance of life. Skin consists of two major layers: an outer layer and an inner layer.
  • the “inner layer” of skin is the dense connective tissue below the outer layer and is “corium,” “cutis,” or “dermis.” It is composed of a dense interlacing network of fibrous connective tissue carrying with it blood vessels, nerves, glands, and hair follicles.
  • Skin is prone to being damaged in many ways, i.e. acne, cyst-like inflammations, eczema, psoriasis, dermatitis, and the like.
  • the damage caused by these non- cancerous conditions is substantially different from the damage caused by cancer.
  • U.S. Pat. No. 5,672,590 discloses a composition for treating cancer comprising a ribose compound, alpha-alanine, ascorbic acid, and nicotinic acid.
  • PCT publication WO 97/26893 discloses another cancer-treating composition which contains a ribose compound, beta-alanine, ascorbic acid, and nicotinic acid.
  • a skin cream composition containing alpha-alanine, a ribose compound, ascorbic acid, nicotinic acid, and a water-based cream is safe and effective in treating skin damage caused by non-cancerous conditions .
  • the present invention is directed to a topical skin cream composition that is safe and effective in treating skin damage caused by acne, eczema, psoriasis, dermatitis, and other similar non-cancerous skin conditions.
  • the composition generally comprises a water-based topical cream, alanine, one or more ribose compounds, ascorbic acid, and nicotinic acid.
  • the composition further contains a physiological saline solution for ease of preparation.
  • the composition further includes salicylic acid.
  • the present invention is directed to a topical skin cream composition containing a water-based topical cream, alanine, one or more ribose compounds, ascorbic acid, and nicotinic acid.
  • the composition further contains a physiological solution for ease of preparation.
  • the composition further contains salicylic acid.
  • the water-based topical cream may be any topical cream base, e.g. vanishing cream or the like, that can be combined with the other ingredients of the composition and form an effective skin cream composition.
  • suitable water based topical creams contain one or more of the following ingredients: polyoxyl stearate 40, stearic acid, cetyl alcohol, stearyl alcohol, isopropyl myristate, xanthine gum, sorbic acid, methyl paraben, propyl paraben, distilled water.
  • Cremori aquasorbi is a preferred cream base.
  • Other structurally or functionally equivalent cream bases are within the scope of this invention.
  • the water-based cream is generally present in an amount of at least 1 wt %, preferably at least 20 wt %, and more preferably at least 25 wt %, based on the total weight of the composition. Suitable amounts ordinarily range from about 1 to about 99 wt %, preferably from about 20 to about 60 wt %, and more preferably from about 25 and about 40 wt %, based on the total weight of the composition. Other ranges within the ranges expressly disclosed above may also be suitable .
  • Alanine is a known material that can be obtained from manufacturers such as Sigma Aldrich and Merck as either alpha- alanine or beta-alanine. While either may be used in the present invention, currently alpha-alanine is preferred. Any iso er of alpha alanine may be used, i.e. D-alpha alanine, L-alpha-alanine, or any mixture thereof. Preferably, a mixture of D- and L-alpha alanine is used.
  • the alpha-alanine is generally present in an amount of at least 0.01 wt %, preferably at least 0.02 wt %, and more preferably at least 0.04 wt %, based on the total weight of the composition.
  • Suitable amounts ordinarily range from about 0.01 to about 7 wt %, more preferably from about 0.02 and about 3 wt %, more preferably from about 0.04 to about 1 wt %, based on the total weight of the composition. Other ranges within the ranges expressly disclosed above may also be suitable.
  • L-beta- alanine is the most preferred form of beta-alanine.
  • the ribose compound may be any ribose compound that includes but is not limited to ribose, deoxyribose (2-deoxy-D-ribose) , other ribose derivatives, and mixtures thereof.
  • suitable ribose compounds include but are not limited to D-ribose, D-ribose 1-phosphate cyclohexylamine salt, D-ribose 5-phosphate barium salt hexahydrate, D-ribose 5-phosphate disodium salt dihydrate, and 2-deoxy-alpha-D-ribose-l-phosphate bis (cyclohexylamine) salt.
  • Other structurally or functionally equivalent ribose compounds are within the scope of this invention.
  • the ribose compound (or mixture of compounds) is ordinarily present at an amount of at least 0.01 wt %, preferably at least 0.05 wt %, and more preferably at least 0.075 wt %, based on the total weight of the composition.
  • Suitable amounts of ribose compounds ordinarily range from about 0.01 to about 20 wt %, preferably from about 0.05 to about 5 wt %, and more preferably from about 0.075 to about 2 wt %, based on the total weight of the composition. Other ranges within the ranges expressly disclosed above may also be suitable.
  • Ascorbic acid is a known compound. Ascorbic acid is ordinarily present at an amount of at least 0.01 wt %, preferably at least 0.05 wt %, and more preferably at least 0.075 wt %, based on the total weight of the composition. Suitable amounts ordinarily range from about 0.01 to about 10 wt %, more preferably from about 0.05 to about 3 wt %, and more preferably from about 0.075 to about 1 wt %, based on the total weight of the composition. Other ranges within the ranges expressly disclosed above may also be suitable.
  • Nicotinic acid is generally present in an amount of at least 0.001 wt %, preferably at least 0.01 wt %, and more preferably at least 0.02 wt %, based on the total weight of the composition. Suitable ranges ordinarily extend from about 0.001 to about 7 wt %, more preferably from about 0.01 to about 1 wt %, and more preferably from about 0.02 to about 0.5 wt %, based on the total weight of the composition. Other ranges within the ranges expressly disclosed above may also be suitable.
  • the physiological solution may be any physiological solution which can be combined with the other, ingredients -of the skin cream composition. Preferably, a physiological saline solution is used.
  • the physiological solution is ordinarily present at an amount of at least 0.03 wt %, preferably at least 0.5 wt %, and more preferably at least 5 wt %, based on the total weight of the composition.
  • Suitable amounts ordinarily range from about 0.03 to about 30 wt %, more preferably from about 0.5 to about 10 wt %, and more preferably from about 5 to about 8 wt %, based on the total weight of the composition.
  • Other ranges within the ranges expressly disclosed above may also be suitable.
  • Salicylic acid is a known material that can be commercially obtained. While the salicylic acid is generally present in an amount of at least 0.5 wt %, it may be present in the range from about 0.1 to about 20 wt %, and even more preferably from about 0.5 to about 2 wt %, based upon the total weight of the composition. Other ranges may also be suitable.
  • the composition may also contain an adenosine compound, i.e. adenosine or an adenosine derivative that is advantageous to the metabolic activity of cells.
  • the adenosine compound will ordinarily be an adenosine triphosphate-forming compound such as a nicotinic acid derivative or precursor thereof.
  • Suitable such nicotinic acid derivatives include nicotinamide adenine dinucleotide, hydronicotinamide adenine dinucleotide, nicotinamide adenine dinucleotide phosphate, beta-nicotinamide adenine dinucleotide monohydrate, beta-nicotinamide adenine dinucleotide dihydrate, beta-nicotinamide adenine dinucleotide phosphate disodium salt, beta-nicotinamide adenine dinucleotide phosphate sodium salt, beta-nicotinamide adenine dinucleotide phosphoric acid, beta- nicotinamide mononucleotide.
  • Adenosine monophosphate may be used as a precursor to nicotinamide adenine dinucleotide.
  • Other structurally or functionally equivalent adenosine compounds may also be suitable.
  • examples of some other adenosine compounds include, but are not limited to, adenosine-5' -monophosphate disodium salt, adenosine-3 ' 5' -cyclophosphate sodium salt monohydrate, adenosine-3' 5' -cyclophosphoric acid, adenosine deaminase, adenosine-5' diphosphate disodium salt, adenosine-5' - diphosphate monopotassium salt dihydrate, adenosine-5' - diphosphoric acid, adenosine-5' - [6, ⁇ -imido] triphosphate tetralithium salt dihydrate, adenosine-5' - [CU, jS-methylene] diphosphoric acid
  • the adenosine compound when used, is generally present at an amount of at least 0.01 wt %, preferably at least 0.02 wt %, and more preferably at least 0.04 wt %, based on the total weight of the composition. Suitable amounts ordinarily range from about 0.01 to about 5 wt %, more preferably from about 0.02 and about 3 wt %, more preferably from about 0.04 to about 1 wt %, based on the total weight of the composition. Other ranges within the ranges expressly disclosed above may also be suitable.
  • the skin cream composition further contains one or more moisturizers .
  • moisturizers include but are not limited to oleum helianthi (sunflower oil) , evening primrose oil, ung. glycerini (pure medical glycerine) , cera alba (pure white sterile medical/cosmetic wax) , aloe vera, jojoba oil, and safflower oil.
  • Other structurally or functionally equivalent moisturizers are also within the scope of the present invention. It is believed that evening primrose oil and/or jojoba oil, in addition to being moisturizers, may enhance the effectiveness of the composition for treating acne.
  • the moisturizers are ordinarily present at an amount of at least 1 wt %, preferably at least 10 wt %, and more preferably at least 40 wt %, based on the total weight of the composition. Suitable amounts ordinarily range from about 1 to about 80 wt %, more preferably from about 10 to about 75 wt %, and more preferably from about 40 to about 70 wt %, based on the total weight of the composition. Other ranges within the ranges expressly disclosed above may also be suitable.
  • oils and vitamins such as vitamin A, vitamin B, vitamin C, vitamin D, vitamin E, vitamin F (essential fatty acids) , vitamin K, juniper essential oil (Juniperus communis) , tea tree essential oil (Melaleuca alterni folia ) , chamomile roman essential oil (Anthemis nobilis) and petitgrain essential oil (Citrus aurantium) may be used.
  • oils are ordinarily present at an amount of at least 0.1 wt %, preferably at least 1 wt %, and more preferably at least 2 wt %, based on the total weight of the composition.
  • Suitable amounts ordinarily range from about 0.1 to about 20 wt %, more preferably from about 1 to about 10 wt %, and more preferably from about 2 to about 5 wt %, based on the total weight of the composition. Other ranges within the ranges expressly disclosed above may also be suitable.
  • the skin cream composition of this invention may be made by combining suitable amounts of the water-based cream, ribose compound, alanine, ascorbic acid, nicotinic acid, physiological saline, and any optional ingredients including salicylic acid in a mixing vessel.
  • the ingredients may be mixed conventionally, i.e. by stirring, until a substantially homogenous mixture is obtained.
  • the mixing time required to form the homogenous mixture depends on factors such as the temperature,- the degree of mixing, and the like.
  • the mixing temperature is preferably about room temperature, but is not critical provided that the temperature is not so high as to harm any of the individual ingredients.
  • the topical skin cream composition is preferably made by forming one or more separate pre-mixtures of ingredients and then combining the pre-mixtures.
  • the composition may be prepared by a method involving (i) forming a first pre-mixture of the alanine, ribose compound(s), ascorbic acid, and nicotinic acid, in a physiological solution, (ii) forming a second pre- mixture of a water-based topical cream and moisturizers, if any, and (iii) combining the two pre-mixtures prior to use.
  • an adenosine compound it is preferably added to the first pre-mixture.
  • salicylic acid is used, it is preferably incorporated into the second pre-mixture.
  • the ascorbic acid, ribose compound, alpha-alanine and nicotinic acid may be sequentially dissolved in a saline solution in a vessel in a sterile environment and mixed until a homogenous mixture forms. Once the ingredients of this pre-mixture are dissolved, they are processed through a filter to remove undissolved particles. This first pre-mixture is then preferably placed in an air tight container and left in a dry, cool and dark environment (refrigerator) for a period of at least about 6 hours .
  • the second pre-mixture may be made by blending the water- based cream, salicylic acid, and any moisturizers in a sterile preparation dish, i.e. a mixing dish, in a water bath heated to a suitable temperature, e.g. from about 80 to 95°C.
  • a suitable temperature e.g. from about 80 to 95°C.
  • the cream base is ordinarily not placed in a mixing dish in a water bath.
  • the acid is preferably added after the moisturizers. Once added, the ingredients are mixed until fully dissolved.
  • the first and second pre-mixtures may then be mixed in a vessel at a cool temperature, e.g. from about 5 to about 15°C.
  • a cool temperature e.g. from about 5 to about 15°C.
  • the above selection of pre-mixtures is illustrative and pre- mixtures having other combinations of ingredients are possible.
  • the skin cream composition is typically refrigerated. Preferably, the composition is stored away from light.
  • the skin cream composition has a storage stability that ordinarily ranges from about 2 to about 6 months.
  • the skin cream composition may be used to treat damaged skin of skin acne, inflammations such as eczema, dermatitis, psoriasis, and other non-cancerous conditions, including such as post-surgical inflamation and diaper rash.
  • the skin cream composition is applied in an amount that is sufficiently great to cover over damaged skin, e.g. a 1 mm film over the affected area, and the composition is quickly absorbed by the skin.
  • EXAMPLE 1 1 kg of a skin cream composition of this invention was made as follows. A pre-mixture was made by dissolving separately and sequentially 750 mg ascorbic acid, 750 mg of D-ribose and 750 mg of 2-deoxy-D-ribose in a 50 ml of a saline solution. Then 400 mg alpha-alanine and 250 mg nicotinic acid were added and dissolved separately into the saline mixture. Once dissolved, the mixture was filtered through a membrane filter and the pre- mixture was placed in an air-tight container and held in a refrigerator at 3°C for about 6 hours.
  • Example 1 To determine the safety and efficacy.of the composition of Example 1 in reducing skin inflammation, 4 individuals that had recently undergone surgery were selected. The individuals had redness and swollen skin in the area where sutures had been placed. The composition of Example 1 was applied over the suture area, and the inflammation and redness around the sutures were significantly reduced within 72 hours.
  • Example 3 To provide the composition of Example 1 with moisturizing capacity, the procedure of Example 1 was repeated except that the water-based cream was replaced by a second pre-mixture made as follows. 320 g of the water-based cream was placed in a sterile mixing dish that had been placed in a water bath heated to a temperature of about 80 to 95°C. Thereafter, 320 g evening primrose oil, 320 g glycerine, and 40 g cera alba were dissolved into the water-based cream.
  • the second pre-mixture was then cooled and mixed with the other pre-mixture which contained the ascorbic acid, D-ribose, 2-deoxy-D-ribose, alpha-alanine, nicotinic acid, and the saline solution.
  • EXAMPLE 4 To determine the safety and efficacy of the composition of Example 3 in treating teenage facial acne, 25 people (14 to 20 years in age) that had been afflicted with continuously recurring acne for several months or even years were selected. The skin cream composition was applied on the acned faces twice daily for 25 consecutive days. The results are shown in Table 1.
  • EXAMPLE 5 To determine the safety and efficacy of the composition in treating adult facial acne, the procedure of Examples 1 and 2 was repeated except that the water-based cream base was replaced with a mixture of 320 g cream base, 160 g evening primrose oil, 160 g oleum helianthi, 320 g glycerine, and 40 g cera alba.
  • EXAMPLE 6 To determine the safety and efficacy of the composition in treating back acne, 15 adults afflicted with back acne were selected for treatment. The composition of Example 5 was applied on their backs twice daily for 14 days and thereafter once daily for a period of an additional 10 weeks. The results are in Table 2.
  • EXAMPLE 7 The procedure of Examples 1 and 2 were repeated except that the water-based cream was replaced with a composition of 320 g water based cream base, 160 g evening primrose oil, 160 g oleum helianthi, 160 g jojoba oil, 160 g glycerine, and 40 g cera alba. In addition, 0.5 wt % of salicylic acid was added. To determine the safety and efficacy of this composition in treating facial acne, 15 people (15 to.25 years in age) who had been afflicted with continuously recurring acne for several months or years were selected. The skin cream composition was applied on the affected areas once or twice daily (depending on the severity of the problem and on the dryness of the skin) for 25 consecutive days. Table 3 indicates the results.
  • a skin cream composition of this invention was made as follows: A pre-mixture was made by dissolving separately and sequentially 2.25 g ascorbic acid, 2.25 g D-ribose, and 2.25 g 2-deoxy- D-ribose in 100 ml physiological saline solution. Then 1.2 g D,L-alpha-alanine and 0.75 g nicotinic acid were added and dissolved separately into the saline mixture. The mixture was filtered, placed in an air-tight container, and left in a refrigerator at 3°C for about 6 hours.
  • a second pre-mixture was made as follows: 320 g of the water-based cream base was placed in a sterile mixing dish in a water bath heated to a temperature of about 80-95°C. Then, 160 g evening primrose oil, 160 g oleum helianthi, 160 g jojoba oil, 160 g glycerine, and 40 g cera alba were dissolved into the cream base. This second pre-mixture was cooled and mixed with the first pre-mixture. To determine the efficacy and safety of the composition of this Example in treating facial acne, 15 p ⁇ ople (15-25 years of age) that had been afflicted with continuously recurring acne for several months or years were selected. The skin cream composition was applied on the affected areas once or twice daily (depending on the severity of the problem and on the dryness of the skin) for 25 consecutive days. Table 4 indicates the results.
  • the skin cream composition was safe and effective for treating facial acne.
  • EXAMPLE 9 To determine the safety and efficacy of the composition of Example 8 in treating contact dermatitis, six (6) people who were afflicted with contact dermatitis were selected. Four of these individuals had been previously treated with other topical medications containing corticoids resulting in worsening of the condition. The skin cream composition was applied on the affected areas twice daily for 20 consecutive days. Table 5 shows the results .
  • the skin cream composition effectively treated dermatitis EXAMPLE 10
  • 5 people who had been afflicted with eczema affecting either their feet, arms, or scalp were selected.
  • the skin cream composition was applied on the affected areas twice daily for 20 consecutive days. Table 6 indicates the results.
  • EXAMPLE 11 To determine the safety and efficacy of a variation of the composition of Example 8 in treating back acne, the composition was made as in Example 8 except that 0.5 wt % salicylic acid was added to the first pre-mixture.
  • This skin cream composition was safe and effective for treating back acne.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Birds (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Cosmetics (AREA)

Abstract

L'invention concerne une composition de crème pour l'épiderme, à usage local, contenant une crème à base d'eau à usage local, de l'alanine, un composé de ribose, de l'acide ascorbique et de l'acide nicotinique. Ladite composition est inoffensive et efficace dans le traitement des lésions de l'épiderme dues à l'acné, à l'eczéma, au psoriasis, à la dermatite et à d'autres états non cancéreux. Elle peut, en outre, contenir une solution saline, de l'acide salicylique et des hydratants. L'invention porte aussi sur un procédé d'utilisation de ladite composition.
PCT/US1998/007430 1997-04-16 1998-04-15 Composition de creme pour l'epiderme WO1998046206A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU69694/98A AU6969498A (en) 1997-04-16 1998-04-15 Skin cream composition

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US4319397P 1997-04-16 1997-04-16
US60/043,193 1997-04-16
US5185097P 1997-07-07 1997-07-07
US60/051,850 1997-07-07

Publications (1)

Publication Number Publication Date
WO1998046206A1 true WO1998046206A1 (fr) 1998-10-22

Family

ID=26720131

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1998/007430 WO1998046206A1 (fr) 1997-04-16 1998-04-15 Composition de creme pour l'epiderme

Country Status (2)

Country Link
AU (1) AU6969498A (fr)
WO (1) WO1998046206A1 (fr)

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002067891A1 (fr) * 2001-02-26 2002-09-06 Columbus Composition cosmetique a base de nicotine libre et utilisations
DE10133196A1 (de) * 2001-07-07 2003-01-23 Beiersdorf Ag Nicotinsäure enthaltende kosmetische und dermatologische Zubereitungen zur Behandlung und aktiven Prävention trockener Haut und anderer negativer Veränderungen der physiologischen Homöostase der gesunden Haut
DE10133199A1 (de) * 2001-07-07 2003-01-23 Beiersdorf Ag Cineol enthaltende kosmetische und dermatologische Zubereitungen zur Behandlung und aktiven Prävention trockener Haut und anderer negativer Veränderungen der physiologischen Homöostase der gesunden Haut
DE10133197A1 (de) * 2001-07-07 2003-01-23 Beiersdorf Ag Aminosäuren enthaltende kosmetische und dermatologische Zubereitungen zur Behandlung und aktiven Prävention trockener Haut und anderer negativer Veränderungen der physiologischen Homöostase der gesunden Haut
EP1417954A1 (fr) * 2002-10-18 2004-05-12 Bernhard Heising Compositions cosmétiques contenant le ribose
FR2861595A1 (fr) * 2003-10-29 2005-05-06 Oreal Composition de peeling comprenant de la vitamine b3 et de la vitamine c
EP2428212A1 (fr) * 2010-09-13 2012-03-14 Marianne Brøndlund Mélange de matière, utilisation et solution d'infusion comprenant de la ribose, de l'alanine, de l'acide nicotinique et de l'acide ascorbique
US9597271B2 (en) 2013-10-24 2017-03-21 The Procter & Gamble Company Cosmetic compositions and methods
US11166968B2 (en) * 2015-09-29 2021-11-09 Kimberly-Clark Worldwide, Inc. Synergistic composition for maintenance of healthy balance of microflora
WO2024104742A1 (fr) * 2022-11-15 2024-05-23 Unilever Ip Holdings B.V. Procédé d'inhibition de croissance de microbes

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0103878A2 (fr) * 1982-09-17 1984-03-28 Humán Oltoanyagtermelö és Kutato Intézet Préparations pour le traitement des plaies de la surface de la peau et procédé pour leur obtention
EP0107885A1 (fr) * 1982-10-29 1984-05-09 Crinos Industria Farmacobiologica S.p.A. Préparations cosmétiques favorisant la nutrition de la peau et des follicules pileux adjacents
US4937234A (en) * 1988-08-10 1990-06-26 Fahim Mostafa S Minerals in bioavailable form
WO1993010802A1 (fr) * 1991-12-02 1993-06-10 Randolph Riemschneider Extraits synthetiques aqueux d'organes

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0103878A2 (fr) * 1982-09-17 1984-03-28 Humán Oltoanyagtermelö és Kutato Intézet Préparations pour le traitement des plaies de la surface de la peau et procédé pour leur obtention
EP0107885A1 (fr) * 1982-10-29 1984-05-09 Crinos Industria Farmacobiologica S.p.A. Préparations cosmétiques favorisant la nutrition de la peau et des follicules pileux adjacents
US4937234A (en) * 1988-08-10 1990-06-26 Fahim Mostafa S Minerals in bioavailable form
WO1993010802A1 (fr) * 1991-12-02 1993-06-10 Randolph Riemschneider Extraits synthetiques aqueux d'organes

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002067891A1 (fr) * 2001-02-26 2002-09-06 Columbus Composition cosmetique a base de nicotine libre et utilisations
DE10133196A1 (de) * 2001-07-07 2003-01-23 Beiersdorf Ag Nicotinsäure enthaltende kosmetische und dermatologische Zubereitungen zur Behandlung und aktiven Prävention trockener Haut und anderer negativer Veränderungen der physiologischen Homöostase der gesunden Haut
DE10133199A1 (de) * 2001-07-07 2003-01-23 Beiersdorf Ag Cineol enthaltende kosmetische und dermatologische Zubereitungen zur Behandlung und aktiven Prävention trockener Haut und anderer negativer Veränderungen der physiologischen Homöostase der gesunden Haut
DE10133197A1 (de) * 2001-07-07 2003-01-23 Beiersdorf Ag Aminosäuren enthaltende kosmetische und dermatologische Zubereitungen zur Behandlung und aktiven Prävention trockener Haut und anderer negativer Veränderungen der physiologischen Homöostase der gesunden Haut
EP1417954A1 (fr) * 2002-10-18 2004-05-12 Bernhard Heising Compositions cosmétiques contenant le ribose
FR2861595A1 (fr) * 2003-10-29 2005-05-06 Oreal Composition de peeling comprenant de la vitamine b3 et de la vitamine c
EP1529522A1 (fr) * 2003-10-29 2005-05-11 L'oreal Composition de peeling comprenant de la vitamine B3 et de la vitamine C
EP2428212A1 (fr) * 2010-09-13 2012-03-14 Marianne Brøndlund Mélange de matière, utilisation et solution d'infusion comprenant de la ribose, de l'alanine, de l'acide nicotinique et de l'acide ascorbique
DE102010045185A1 (de) * 2010-09-13 2012-03-15 Marianne Broendlund Stoffgemisch, Verwendung und Infusionslösung
US9597271B2 (en) 2013-10-24 2017-03-21 The Procter & Gamble Company Cosmetic compositions and methods
US11166968B2 (en) * 2015-09-29 2021-11-09 Kimberly-Clark Worldwide, Inc. Synergistic composition for maintenance of healthy balance of microflora
WO2024104742A1 (fr) * 2022-11-15 2024-05-23 Unilever Ip Holdings B.V. Procédé d'inhibition de croissance de microbes

Also Published As

Publication number Publication date
AU6969498A (en) 1998-11-11

Similar Documents

Publication Publication Date Title
EP0129003B2 (fr) Compositions cosmétiques et dermatologiques contenant du 1-alpha-hydroxycholecalciférol
EP0715852B1 (fr) Utilisation de l'acide hyaluronique ou son sel pour le traitement des désordres de la peau
US6096326A (en) Skin care compositions and use
JP5028480B2 (ja) 手足症候群の治療のためのアロプリノールの使用
EP0644766B1 (fr) Composition dermatologique contenant de l'oxyde azote
WO1999059580A1 (fr) Agents preventifs/therapeutiques pour les affections cutanees
EP0146742A1 (fr) Utilisation de l'ubidecarénone pour l'obtention d'un médicament destiné à traiter des ulcères causés par radiothérapie
JP2002506801A (ja) 哺乳類の皮膚のセルライトを軽減する方法
WO1998046206A1 (fr) Composition de creme pour l'epiderme
AU2006201726B2 (en) Formulation for dermal application
CN111773272A (zh) 一种治疗痤疮的外用复合配方及其制备方法
JP2024059876A (ja) 創傷および皮膚障害を治療するためのタラ肝油で構成される局所用組成物
WO2013050959A1 (fr) Composition pour le traitement de lésions de la peau
US10383908B1 (en) Inducing granulation tissue in third-degree skin burns using topical Hamelia patens extract
US8313756B1 (en) Urea compositions and their methods of manufacture
KR20120049848A (ko) 수족 피부반응 치료를 위한 알로푸리놀의 이용
JPH0782131A (ja) ヒアルロニダーゼ活性阻害剤及び水中油型クリーム基剤
JPS6339813A (ja) 創傷治療剤
KR960005144B1 (ko) 상처 치유 촉진용 조성물
RU2371172C2 (ru) Фармацевтическая композиция местного и наружного применения для лечения травматических и послеоперационных повреждений периферической нервной системы на основе стефаглабрина
EP0747040A1 (fr) Pétrolatum avec de phosphates d'inositol
JP4610705B2 (ja) 皮膚外用剤
CN108125967A (zh) 一种用于缓解银屑病的敷料及制备方法
CN106913515B (zh) 一种重建皮肤屏障稳态的牛磺酸螯合钙外用制剂及其应用
WO1997018804A1 (fr) Rajeunissement de la peau a l'aide d'une combinaison de vitamine a et d'acides alphahydroxy

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM GW HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

NENP Non-entry into the national phase

Ref country code: JP

Ref document number: 1998544178

Format of ref document f/p: F

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: CA